Nektar Therapeutics to release third-quarter earnings on November 12

Nektar Therapeutics (Nasdaq: NKTR) is scheduled to release its financial results for the quarter ending September 30, 2026, on Thursday, November 12. The announcement will occur after the close of regular trading on U.S. financial markets.

Following the release, President and CEO Howard Robin will lead a conference call and webcast to discuss the company’s performance and operational updates. The call serves as a primary opportunity for shareholders and analysts to evaluate the company's financial position and the progress of its drug development pipeline.

Nektar Therapeutics focuses on immunology and oncology therapeutics. Stakeholders will be looking for data regarding the company's research expenditures and progress in clinical trial developments reported over the three-month period.